Reports that the use of diagnostic test which detect overexpression of the HER2 antigen to identify breast cancer patients likely to benefit from Herceptin lack pharmacogenomics. Usage of the genotype to segregate responding from non-responding patients; Measurement of a phenotype unlinked to genotype during a test for HER2 overexpression.